what aod-9604 actually is
AOD-9604 stands for Anti-Obesity Drug 9604 — the development name from Metabolic Pharmaceuticals, the Australian company that originally developed the molecule. It's a 16-amino-acid fragment of human growth hormone, specifically the C-terminal sequence (amino acids 177-191) with a tyrosine added at the front for stability.
This matters because HGH itself does multiple distinct things from a single sequence. It stimulates IGF-1 production (driving muscle growth and tissue maintenance). It affects blood glucose regulation. And separately from both of those, it mobilizes stored fat for energy. Each of these activities is associated with a different region of the HGH molecule. Researchers in the 1990s mapped these regions and found that the fat-mobilizing activity was localized to the C-terminal end. AOD-9604 is essentially that C-terminal piece, isolated.
The design hypothesis: keep the fat-mobilizing activity, lose the muscle-and-blood-sugar effects, get a cleaner anti-obesity tool without the metabolic complications of full HGH.
how fat mobilization actually works
To understand why this fragment matters, you need a quick read on lipolysis — the process by which stored fat gets pulled out of fat cells and turned into usable energy.
Fat is stored in adipocytes as triglycerides — three fatty-acid chains bound to a glycerol backbone. To actually use that stored fat, your body has to:
1. Activate hormone-sensitive lipase, the enzyme that cleaves triglycerides into free fatty acids and glycerol 2. Release the free fatty acids out of the fat cell into the bloodstream 3. Transport them to muscle and other tissues that can burn them for energy 4. Burn them in mitochondria via beta-oxidation
Full HGH activates this whole pathway through receptors on adipocytes. The C-terminal region of HGH — what AOD-9604 isolates — is responsible for the lipolysis-activation step specifically.[1]
What AOD-9604 does NOT do is activate the IGF-1 pathway (which drives muscle growth and the broader anabolic effects of HGH) or the parts of HGH that affect insulin sensitivity. It's a more selective tool than full HGH — narrowly focused on fat metabolism.
what the research actually shows
The preclinical research on AOD-9604 is reasonably consistent. In rodent obesity models, AOD-9604 administration produces measurable fat-mass reduction without affecting muscle mass or IGF-1 levels — exactly what the design hypothesis predicted.[1]
In the early-2000s human clinical development, Metabolic Pharmaceuticals ran several trials, including a Phase 2b randomized controlled trial in obese adults. The headline result was modest — AOD-9604 produced statistically significant but clinically small fat-mass reduction over 12 weeks compared to placebo, in the range of 1-2% of body weight.[2] The trial didn't show the dramatic obesity-treatment effect the company had hoped for, and the molecule didn't progress to FDA approval as an obesity drug.
This is worth being clear about: the human evidence supports AOD-9604 as a real but modest fat-mobilizing molecule, NOT as a substitute for GLP-1 drugs (which produce 15-20% body-weight reductions in their target population). AOD-9604 is in a different effect-size category. It's an honest tool with real biology behind it — it's not a transformative obesity treatment.
What the molecule has since found a niche in is functional medicine practice for body-recomposition contexts. Patients who aren't obese but want to reduce specific stubborn fat depots while preserving muscle. AOD-9604's selectivity — no muscle-loss risk because it doesn't affect IGF-1 — makes it appealing for that use case.
why it's sometimes used topically
One distinctive feature of AOD-9604 in functional medicine and aesthetic medicine spaces is topical formulation. The molecule has been compounded into creams applied to specific body regions — most often the abdomen — with the rationale that local application produces local lipolysis effects without requiring systemic exposure.
The research on topical AOD-9604 is much thinner than on injected forms. A few small studies have suggested local fat-mobilization effects from topical application, but the evidence base doesn't approach the level needed to confidently recommend the topical route over injection. Most clinicians who've used AOD-9604 in body-recomposition contexts use the injectable form for systemic effect.
The topical-cream approach is probably best understood as: the molecule has selective fat-mobilization activity, topical application probably produces some local effect, and the safety profile is clean enough that local application carries low downside risk. Whether it's clinically meaningful is honestly an open question.
how it stacks up against other fat-targeting tools
It's useful to place AOD-9604 alongside the other tools that exist for fat reduction:
GLP-1 drugs (Ozempic/Wegovy/tirzepatide). Different mechanism entirely (appetite suppression + insulin sensitivity), much larger effect size (15-20% body weight reduction), FDA-approved for obesity. AOD-9604 is not a substitute or even a competitor — they target different physiology.
Tesamorelin (FDA-approved for HIV-associated lipodystrophy). A GHRH analog that produces visceral fat reduction through GH-axis stimulation. Larger and more reliable visceral-fat effects than AOD-9604, but produces full GH-axis effects (IGF-1 elevation, etc.) rather than AOD-9604's selective profile. Currently legally prescribable.
Lipotropic injections (B12, MIC, choline, methionine). Different mechanism (liver fat metabolism support, not lipolysis). Modest effects. Widely available but research support is weak.
Orlistat / lipase inhibitors. Block dietary fat absorption rather than mobilizing stored fat. Different problem, different solution.
In this landscape, AOD-9604's specific niche is selective lipolysis without GH-axis effects — useful if you specifically don't want IGF-1 elevation or muscle effects, accept a modest effect size, and have access to legitimate compounding supply.
where this leaves you
AOD-9604 occupies an interesting niche in peptide pharmacology — a selectively engineered fragment that demonstrates real but modest fat-mobilization activity without the broader effects of full HGH. The mechanism is well-grounded. The human clinical evidence is consistent but modest in effect size.
For someone trying to figure out whether AOD-9604 is worth thinking about in their own context, the honest framing:
- It's a tool for body recomposition (selective fat reduction with muscle preservation), not for obesity treatment - Effect size is modest (1-2% body fat over weeks), not transformative - It's mechanistically different from GLP-1 drugs and doesn't compete with them on effect size - It's currently in regulatory limbo in the US pending FDA's Cat 2 reclassification - When it returns to legal compounding, it'll be one option among several in the body-comp toolkit alongside Tesamorelin and lipotropic protocols
For the broader peptide regulatory framework, see are peptides legal in 2026. For the reality-check on what a single cycle actually delivers, see the AOD-9604 reality check.
Sources & references
- [1]Heffernan M, Summers RJ, Thorburn A, et al. 'The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta3-AR knock-out mice.' Endocrinology, 2001; 142(12):5182-5189. ↩
- [2]Ng FM, Sun J, Sharma L, et al. 'Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.' Hormone Research, 2000; 53(6):274-278. ↩
- [3]Stier H, Vos E, Kenley D. 'Safety and tolerability of the hexadecapeptide AOD9604 in humans.' Journal of Endocrinology and Metabolism, 2013; 3(1-2):7-15. ↩
Editorial & medical disclaimer
This article is published by the Pepvio editorial team for informational purposes only. It is not medical advice, diagnosis, or treatment, and it has not been reviewed by a licensed clinician. The information presented draws on published research but should not substitute for professional medical guidance. Pepvio protocols require a prescription from a licensed healthcare provider. Individual results vary. Always consult your physician before starting any new treatment protocol. Pepvio does not claim that any product cures, treats, or prevents any disease.
Ready to explore peptide therapy and hormone optimization?
Take our 2-minute health assessment to see which Pepvio protocol fits your goals. A licensed provider reviews every response.
Find My ProtocolKeep reading
Thymosin Alpha-1: The Immune Peptide Approved in 35+ Countries (But Not the US)
Thymosin Alpha-1 has 40+ years of clinical research and approval as a prescription medication in dozens of countries. Here's what the science actually shows about this immune-modulating peptide — and the regulatory limbo it sits in stateside.
Read articleGHK-Cu: The Copper Peptide Behind 50+ Years of Collagen Research
GHK-Cu is a copper-binding peptide first isolated from human plasma in the 1970s. Five decades of research point to real effects on collagen, wound healing, and the visible signs of aging skin. Here's what the published evidence actually shows — and where the marketing has outrun it.
Read articleCJC-1295/Ipamorelin: The Growth Hormone Peptide Stack Explained
CJC-1295 and Ipamorelin together are the most-discussed GH-axis peptide combination in biohacker culture. Here's how each one works, why they pair the way they do, and what the research actually describes about effects on sleep, body composition, and recovery.
Read article